Scholar Rock Holding Corporation $SRRK Shares Bought by Granahan Investment Management LLC

Granahan Investment Management LLC raised its position in Scholar Rock Holding Corporation (NASDAQ:SRRK) by 77.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 129,914 shares of the company’s stock after buying an additional 56,539 shares during the period. Granahan Investment Management LLC’s holdings in Scholar Rock were worth $4,838,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of SRRK. Ramirez Asset Management Inc. purchased a new stake in shares of Scholar Rock during the 3rd quarter worth about $37,000. Penserra Capital Management LLC purchased a new position in shares of Scholar Rock in the 3rd quarter valued at about $56,000. Strs Ohio acquired a new position in Scholar Rock in the 1st quarter worth about $77,000. Bessemer Group Inc. boosted its position in Scholar Rock by 970.0% during the third quarter. Bessemer Group Inc. now owns 2,322 shares of the company’s stock worth $86,000 after purchasing an additional 2,105 shares in the last quarter. Finally, Elevation Point Wealth Partners LLC purchased a new position in Scholar Rock during the second quarter worth approximately $94,000. Institutional investors and hedge funds own 91.08% of the company’s stock.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Mo Qatanani sold 14,898 shares of the firm’s stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $46.71, for a total value of $695,885.58. Following the transaction, the insider owned 85,660 shares in the company, valued at approximately $4,001,178.60. This trade represents a 14.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Vikas Sinha sold 16,755 shares of Scholar Rock stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $715,438.50. Following the sale, the chief financial officer directly owned 583,245 shares in the company, valued at approximately $24,904,561.50. This trade represents a 2.79% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 208,470 shares of company stock worth $9,201,778 in the last quarter. 13.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts have recently commented on SRRK shares. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research report on Thursday, December 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Scholar Rock in a research report on Thursday, January 22nd. Raymond James Financial reissued a “strong-buy” rating on shares of Scholar Rock in a research note on Tuesday, March 3rd. UBS Group initiated coverage on shares of Scholar Rock in a report on Wednesday, January 7th. They issued a “buy” rating and a $60.00 price target for the company. Finally, Barclays upped their price objective on shares of Scholar Rock from $52.00 to $53.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 3rd. Four research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Scholar Rock presently has an average rating of “Buy” and an average target price of $54.14.

Scholar Rock Price Performance

Shares of Scholar Rock stock opened at $40.01 on Monday. The business has a 50 day simple moving average of $45.21 and a two-hundred day simple moving average of $39.68. Scholar Rock Holding Corporation has a 12 month low of $22.71 and a 12 month high of $49.82. The stock has a market capitalization of $4.60 billion, a P/E ratio of -11.66 and a beta of 0.70. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.95 and a quick ratio of 6.95.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Tuesday, March 3rd. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.10. During the same period in the previous year, the company posted ($0.64) earnings per share. As a group, analysts predict that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Scholar Rock Company Profile

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).